Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 29 August 2022, 14:00 HKT/SGT
Share:
    

Source: Malaysian Genomics Resource Centre Bhd
Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region

PETALING JAYA, Malaysia, Aug 29, 2022 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.

Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, and H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group [L-R]

Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private equity, real estate and industrial investments.

As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products. Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the Middle East and North Africa (MENA) region for areas such as agriculture, aquaculture, plantations, healthcare and industrial biotechnology.

Malaysian Genomics on its part will analyse samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.

Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, said, "This is a really good opportunity for us to explore the MENA market for our products and services, especially in the area of R&D where we see a lot of growth especially in agriculture and aquaculture due to climate change impact and the health diagnosis for distinct population groups."

H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group, said, "We look forward to working with Malaysian Genomics to bring its biopharmaceutical and genetic services and products to Saudi Arabia, which is a good launchpad to the MENA region. This MoU is just the beginning as we explore how we can work closely together in the coming months."

About Malaysian Genomics Resource Centre Berhad

Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients. For more information, visit www.mgrc.com.my.


Topic: Press release summary
Source: Malaysian Genomics Resource Centre Bhd

Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Malaysian Genomics Resource Centre Bhd
Aug 29, 2023 13:00 HKT/SGT
Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals
May 15, 2023 18:00 HKT/SGT
Malaysian Genomics Inks Agreement in Expansion to Bangladesh
Feb 27, 2023 13:00 HKT/SGT
Malaysian Genomics to Boost Play on the Football Pitch
Feb 24, 2023 17:30 HKT/SGT
Malaysian Genomics Pivots to Biopharmaceuticals for Growth
Feb 24, 2023 13:30 HKT/SGT
Malaysian Genomics to Collaborate on Cannabinoid R&D
Feb 22, 2023 14:30 HKT/SGT
Malaysian Genomics to Offer World's First DNA-Driven Fertility Test
Jan 9, 2023 14:00 HKT/SGT
Malaysian Genomics Explores R&D Collaboration with SIRIM
Nov 23, 2022 17:30 HKT/SGT
Malaysian Genomics Sees Rise in Profit Margins for 1Q
Oct 26, 2022 19:00 HKT/SGT
Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE
Oct 12, 2022 13:00 HKT/SGT
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: